Strides Pharma Science Ltd logo

Strides Pharma Science Ltd

STAR NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹8,982 Cr
Volatility
Moderate
P/E Ratio
14.26
EBITDA
₹1,076 Cr
Return on Equity
18.24%
Debt to Equity
0.57
Book Value
₹337.15
52W High
₹1,231
52W Low
₹768.65

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Strides Pharma Science Ltd insights

50 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company has delivered good profit growth of 20.1% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%

Weaknesses

4
  • Stock is trading at 2.93 times its book value
  • The company has delivered a poor sales growth of 7.94% over past five years.
  • Promoter holding is low: 27.9%
  • Promoters have pledged 38.1% of their holding.

Growth Rate

Revenue Growth
8.33% ↗
Net Income Growth
40.33% ↗
Cash Flow Change
2.65% ↗
ROE
15.22% ↘
ROCE
-1.27% ↘
EBITDA Margin (Avg.)
15.30% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 43d ago
AI opinion · based on fundamentals
Risk high

Strides Pharma Science (market cap ₹10,347 Cr, PE 18.1x) has delivered strong profit growth over the past 3-5 years with a notable 3-year ROE of 57%, but faces headwinds from decelerating sales growth (TTM at 6%) and a sharp TTM profit decline of -84%. Promoter pledging at 27.3% adds governance risk to an otherwise improving return profile.

Bull Case 7
  • Strong 3-year ROE of 57% indicates efficient capital allocation and high returns on shareholder equity
  • Compounded profit growth of 71% CAGR over 3 years demonstrates significant earnings recovery
  • 5-year compounded profit growth of 21% CAGR reflects sustained long-term earnings expansion
  • Stock CAGR of 76% over 3 years suggests strong market re-rating driven by improving fundamentals
  • PE ratio of 18.1x is reasonable for a pharma company with 20%+ ROE in the last year
  • 10-year compounded profit growth of 16% CAGR shows the business has scaled profitability over a full cycle
  • Dividend yield of 0.35% indicates the company has initiated shareholder returns alongside growth
Bear Case 8
  • TTM compounded profit declined -84%, signalling a sharp and severe earnings reversal in the most recent period
  • Promoters have pledged 27.3% of their holding, raising corporate governance and forced-selling risk
  • 5-year sales CAGR of only 7.94% reflects poor top-line momentum for a mid-cap pharma company
  • Stock trades at 3.34x book value, which is elevated given the recent earnings collapse
  • TTM sales growth has decelerated to just 6%, below the 10-year average of 5% CAGR on a compounded basis
  • Tax rate appears low, which may not be sustainable and could compress future net margins if normalized
  • 10-year stock CAGR of only 8% suggests long-term wealth creation has been inconsistent despite recent rally
  • Debt-to-equity ratio is undisclosed, limiting visibility into the company's leverage and financial risk profile

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 43d ago
Neutral 2
  • Sells Pivot Path stake Jun 27

    Strides Pharma sold its majority stake in Pivot Path to Ascent Capital for Rs 1,000 million. Pivot Path will be reclassified as an associate company.

  • Unrelated STAR ETF launched Jun 9

    BlackRock launched the iShares Space Technologies UCITS ETF under the ticker STAR on Jun 9, 2026, tracking space technology stocks. This is unrelated to Strides Pharma and concerns only a shared ticker symbol in European markets.

TL;DR: A quiet period for Strides Pharma with no material positive or negative catalysts. The Pivot Path divestiture is a minor portfolio restructuring event. The STAR ETF news is unrelated to the company. No clear directional trend emerging from recent newsflow.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
930
999
1,006
1,044
1,054
1,167
1,154
1,190
1,120
1,221
1,195
1,323
1,265
Expenses
796
889
876
874
866
983
943
973
902
990
959
1,084
1,037
Operating Profit
134
111
129
169
188
184
210
218
218
231
236
240
228
OPM %
14%
11%
13%
16%
18%
16%
18%
18%
19%
19%
20%
18%
18%
Other Income
3
-129
60
-27
3,299
25
4
-12
0
18
104
3
68
Interest
76
79
70
71
73
74
52
50
47
46
43
42
41
Depreciation
60
60
49
48
47
48
48
49
49
50
51
53
56
PBT
0
-157
70
23
3,369
86
114
106
122
153
245
148
200
Tax %
3025%
-5%
23%
55%
1%
16%
21%
20%
13%
14%
15%
13%
17%
Net Profit
-9
-149
54
10
3,350
72
90
86
106
132
208
129
165
EPS in Rs
-0.79
-14.54
5.4
1.98
365
7.81
9.54
8.91
10.8
13.84
21.93
13.77
17.02
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,196
2,861
2,755
2,845
2,178
2,752
3,316
3,070
3,688
3,890
4,565
4,859
5,004
Expenses
967
2,486
2,228
2,448
1,982
2,338
2,779
3,201
3,544
3,362
3,763
3,933
4,070
Operating Profit
229
374
527
398
197
414
537
-131
145
528
803
925
935
OPM %
19%
13%
19%
14%
9%
15%
16%
-4.3%
3.9%
14%
18%
19%
19%
Other Income
874
63
291
643
303
-43
109
-112
92
-100
3,313
124
193
Interest
47
168
183
196
79
156
150
177
261
280
249
179
172
Depreciation
64
131
126
154
117
174
206
233
243
214
192
202
210
PBT
992
137
509
690
303
42
289
-653
-268
-65
3,675
669
746
Tax %
15%
31%
12%
1%
-9%
27%
11%
-27%
-21%
45%
2%
14%
—
Net Profit
844
95
446
684
330
31
258
-474
-212
-94
3,598
575
634
EPS in Rs
142
12.15
44.71
74.25
36.27
4.06
29.93
-51.25
-22.44
-7.68
390
60.34
66.56
Div. Payout %
76%
41%
10%
3%
8%
345%
8%
0%
-7%
-33%
1%
8%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
60
89
89
90
90
90
90
90
90
92
92
92
Reserves
1,085
2,569
2,659
2,374
2,559
2,438
2,687
2,269
2,122
2,034
2,460
3,015
Borrowings
892
3,542
3,700
2,520
3,221
2,235
2,348
3,025
3,030
2,517
1,880
1,758
Other Liabilities
438
1,211
1,598
1,601
1,937
1,369
1,844
1,556
1,352
1,157
1,498
1,941
Total Liabilities
2,475
7,410
8,046
6,585
7,807
6,131
6,969
6,940
6,594
5,799
5,929
6,807
Fixed Assets
701
2,679
2,980
2,977
3,648
2,099
2,219
2,347
2,311
1,865
1,899
2,101
CWIP
171
815
780
620
453
413
447
291
151
162
207
447
Investments
630
1,341
1,525
588
702
549
697
540
490
303
409
291
Other Assets
972
2,576
2,762
2,400
3,005
3,070
3,605
3,762
3,642
3,470
3,414
3,967
Total Assets
2,475
7,410
8,046
6,585
7,807
6,131
6,969
6,940
6,594
5,799
5,929
6,807
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
83
73
288
187
60
205
481
-258
44
701
684
703
Investing
50
-2,205
-1,222
570
-145
1,321
-522
-119
302
-150
-90
-173
Financing
-421
2,944
338
-1,016
194
-1,709
-16
421
-214
-693
-643
-453
Net Cash Flow
-288
812
-596
-259
110
-184
-56
45
133
-142
-48
76
Free Cash Flow
-157
-293
-386
-212
-256
58
188
-326
-43
672
505
291
CFO/OP
61
40
66
61
59
60
60
199
-30
128
77
84
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
119
132
132
113
165
124
122
144
129
107
96
97
Inventory Days
135
149
209
146
294
254
329
285
257
235
236
305
Days Payable
153
188
221
188
299
259
323
260
220
178
190
244
Cash Conversion Cycle
102
92
120
71
160
119
128
168
165
164
141
157
Working Capital Days
-91
6
-122
-4
-70
-70
-22
-28
-11
-19
24
38
ROCE %
57%
8%
11%
16%
2%
5%
8%
-5%
0%
7%
15%
18%

Shareholding Pattern

As of Jun 2026
FIIs 28.39%
Promoters 27.91%
Public 20.42%
DIIs 15.41%
Others 7.85%
Government 0.01%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
29.67%
29.62%
29.60%
29.60%
30.60%
30.37%
31.07%
30.89%
28.27%
28.07%
27.78%
27.39%
25.88%
25.86%
25.84%
26.82%
28.30%
28.30%
27.86%
27.86%
27.91%
27.91%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.05%
0.05%
0.05%
0.05%
0.00%
0.00%
24.57%
26.71%
30.08%
28.48%
28.32%
28.02%
28.51%
29.52%
28.68%
28.39%
DIIs
14.82%
13.23%
14.22%
14.85%
12.40%
9.82%
13.59%
18.84%
18.29%
20.00%
18.22%
17.56%
18.04%
18.56%
18.24%
16.92%
13.72%
13.30%
12.98%
13.02%
14.45%
15.41%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
Public
14.01%
16.64%
17.89%
20.42%
21.82%
22.29%
22.40%
22.43%
25.51%
24.93%
23.39%
22.65%
21.19%
20.87%
18.57%
20.86%
21.52%
22.10%
22.44%
21.42%
20.78%
20.42%
Others
41.49%
40.51%
38.29%
35.12%
35.19%
37.51%
32.88%
27.77%
27.86%
26.93%
30.60%
32.39%
10.32%
8.00%
7.26%
6.90%
8.14%
8.27%
8.20%
8.17%
8.17%
7.85%
No. of Shareholders
74,074
96,976
1,06,927
1,25,553
1,33,190
1,34,718
1,30,682
1,23,964
1,20,916
1,12,775
1,01,638
91,182
84,695
91,917
96,009
1,14,236
95,125
92,889
91,206
85,589
86,616
94,856

Documents

Frequently Asked Questions about Strides Pharma Science Ltd

What does Strides Pharma Science Ltd do?
Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new market...
Where is Strides Pharma Science Ltd (STAR) listed?
Strides Pharma Science Ltd is listed on the Indian stock exchanges. It is listed on NSE: STAR and BSE: 532531. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Strides Pharma Science Ltd belong to?
Strides Pharma Science Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has a market capitalisation of approximately ₹8982.23 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Strides Pharma Science Ltd?
The Price-to-Earnings (PE) ratio of Strides Pharma Science Ltd is 14.26. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Strides Pharma Science Ltd?
Over the past 52 weeks, Strides Pharma Science Ltd has traded between a low of ₹768.65 and a high of ₹1,231. This range helps investors understand the stock's price volatility and recent trading levels.
Does Strides Pharma Science Ltd pay dividends?
Yes, Strides Pharma Science Ltd has a dividend yield of 0.51%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Strides Pharma Science Ltd?
Strides Pharma Science Ltd has a Return on Equity (ROE) of 18.24%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Strides Pharma Science Ltd on Tapetide?
On Tapetide, you can view Strides Pharma Science Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Strides Pharma Science Ltd is in the business of development and manufacturing of pharmaceutical products.[1] The company's pharmaceutical products are sold in over 100 countries.[2] The company has always followed an inorganic growth strategy over the years that resulted in foray into new markets, addition of new business segments, therapy segments and manufacturing infrastructure.[3]

Website strides.com
CEO Mr. Arun Kumar Pillai B.Com.
Employees 3,301
Listed 2000-02-02
Face Value ₹ 10
Issued Size 9,21,72,714

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List